Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now early-phase tilt small index

Cytopenia: early-phase trial registry

8 of 12 indexed Cytopenia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 8 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Cytopenia: 12 US clinical trials tracked, 8 recruiting.

Cytopenia is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition cytopenia

OPEN 8 | RECR 67% | LATE 0 | EARLY 7 | RANK #1429 | SPON 2

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Cytopenia (this)67%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Cytopenia

Cytopenia lists 8 open slots (67% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cytopenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cytopenia is recruiting above its size-band peers.

    8 of 12 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cytopenia research.

    M.D. Anderson Cancer Center accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cytopenia enrolment sits around 108 participants.

    Median target enrolment is 108 among the 12 trials that report a genuine target (sentinel values excluded). 6 of those (50%) plan for fewer than 100 participants.

  4. Cytopenia research is mostly interventional.

    11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 25

Open and recent trials

12 total, page 1 of 1

RECRUITING NA 2,000 participants

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Mayo Clinic

NCT02958462

RECRUITING 1,500 participants

Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study

Weizmann Institute of Science

NCT07081087

RECRUITING Phase 2 160 participants

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Takeda

NCT04419649

RECRUITING Early Phase 1 108 participants

Early Intervention in High Risk CCUS

Lachelle D. Weeks, MD, PhD

NCT06802146

RECRUITING Phase 2 40 participants

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

M.D. Anderson Cancer Center

NCT07025512

RECRUITING Phase 2 35 participants

A Study of Emapalumab for Pediatric Aplastic Anemia

Memorial Sloan Kettering Cancer Center

NCT06430788

RECRUITING Phase 2 32 participants

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

M.D. Anderson Cancer Center

NCT06285825

RECRUITING Phase 2 10 participants

Danazol for Treatment of Cytopenias in Patients With Cirrhosis

University of Southern California

NCT04873102

ACTIVE NOT RECRUITING Phase 1 120 participants

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Bellicum Pharmaceuticals

NCT03301168

ACTIVE NOT RECRUITING NA 109 participants

Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies

Rigshospitalet, Denmark

NCT03682029

ACTIVE NOT RECRUITING NA 53 participants

Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.

Meyer Children's Hospital IRCCS

NCT06276036

ACTIVE NOT RECRUITING NA 3 participants

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

Baylor College of Medicine

NCT05236764

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5

Named interventions

Most-linked intervention names on Cytopenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Vitamin C (ascorbic acid) Dietary supplement
1 trials
Identification of specific markers Other
1 trials
BPX-501 T cells Biological
1 trials
Emapalumab Biological
1 trials
Emapalumab Drug
1 trials
Danazol Pill Drug
1 trials
Inqovi Drug
1 trials
Punch Biopsy Procedure
1 trials

US sites by state

Facility locations filed on Cytopenia trials. A trial with sites in several states counts in each.

California 5 trials
Texas 4 trials
Florida 4 trials
Pennsylvania 2 trials
New York 2 trials
Massachusetts 2 trials
Wisconsin 1 trials
Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cytopenia page

12 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cytopenia condition card totals 12 registered trials; most-linked intervention Vitamin C (ascorbic acid); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.